BR112012022552A2 - uso de fenoterol e de anélogos de fenoterol no tratamento de gliobastomas e astrocitomas - Google Patents

uso de fenoterol e de anélogos de fenoterol no tratamento de gliobastomas e astrocitomas

Info

Publication number
BR112012022552A2
BR112012022552A2 BR112012022552A BR112012022552A BR112012022552A2 BR 112012022552 A2 BR112012022552 A2 BR 112012022552A2 BR 112012022552 A BR112012022552 A BR 112012022552A BR 112012022552 A BR112012022552 A BR 112012022552A BR 112012022552 A2 BR112012022552 A2 BR 112012022552A2
Authority
BR
Brazil
Prior art keywords
fenoterol
treatment
analogs
tumor
gliobastomas
Prior art date
Application number
BR112012022552A
Other languages
English (en)
Other versions
BR112012022552A8 (pt
Inventor
Irving W Wainer
Lawrence Robert Toll
Lucita Arenas Jimenez
Michael Bernier
Original Assignee
Stanford Res Inst Int
Us Health
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Stanford Res Inst Int, Us Health filed Critical Stanford Res Inst Int
Publication of BR112012022552A2 publication Critical patent/BR112012022552A2/pt
Publication of BR112012022552A8 publication Critical patent/BR112012022552A8/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

uso de fenoterol e de anélogos de fenoterol no tratamento de gliobastomas e astrocitomas. a presente invenção refere-se à descoberta do uso de fenoterol e análogos de (r,r)- e (r,s)-fenoterol no tratamento de um tumor que expressa um receptor-<225>~ 2~ adrenérgico, tal como tumor cerebral primário, incluindo glioblastoma ou astrocitoma que expressa um receptor-<225>~ 2~ adrenérgico. em um exemplo, o método inclui administrar um análogo de fenoterol específico ou uma combinação destes para reduzir um ou mais sintomas associados ao tumor, tratando assim o tumor do paciente.
BR112012022552A 2010-03-10 2011-03-10 uso de fenoterol e de análogos de fenoterol no tratamento de gliobastomas e astrocitomas e composição farmacêutica compreendendo os referidos compostos BR112012022552A8 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US31264210P 2010-03-10 2010-03-10
PCT/US2011/027988 WO2011112867A1 (en) 2010-03-10 2011-03-10 The use of fenoterol and fenoterol analogues in the treatment of glioblastomas and astrocytomas

Publications (2)

Publication Number Publication Date
BR112012022552A2 true BR112012022552A2 (pt) 2016-08-30
BR112012022552A8 BR112012022552A8 (pt) 2017-12-05

Family

ID=43858307

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112012022552A BR112012022552A8 (pt) 2010-03-10 2011-03-10 uso de fenoterol e de análogos de fenoterol no tratamento de gliobastomas e astrocitomas e composição farmacêutica compreendendo os referidos compostos

Country Status (7)

Country Link
US (4) US9492405B2 (pt)
EP (1) EP2544676B1 (pt)
JP (1) JP5837890B2 (pt)
AU (2) AU2011224241B2 (pt)
BR (1) BR112012022552A8 (pt)
CA (1) CA2791702C (pt)
WO (1) WO2011112867A1 (pt)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013177418A1 (en) 2012-05-25 2013-11-28 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Methods of regulating cannabinoid receptor activity-related disorders and diseases
WO2015153725A2 (en) * 2014-04-03 2015-10-08 Mitchell Woods Pharmaceuticals, Inc. Methods of treating melanoma
EP3125878A4 (en) * 2014-04-03 2017-11-29 Mitchell Woods Pharmaceuticals, Inc. Methods of treating breast cancer
KR101585619B1 (ko) * 2014-11-20 2016-01-15 주식회사 아모텍 감전보호소자 및 이를 구비한 휴대용 전자장치
US20180042867A1 (en) * 2015-03-06 2018-02-15 Mitchell Woods Pharmaceuticals, Inc. Methods of treating cancer
US20180271808A1 (en) * 2015-10-01 2018-09-27 Mitchell Woods Pharmaceuticals, Inc. Methods of reducing chemoresistance and treating cancer
AU2016341109A1 (en) * 2015-10-18 2018-06-07 Onco Therapies Llc Compositions and methods of regulating cancer related disorders and diseases
WO2018022666A1 (en) * 2016-07-26 2018-02-01 Flagship Pioneering, Inc. Neuromodulating compositions and related therapeutic methods for the treatment of cancer by modulating an anti-cancer immune response
GB201714736D0 (en) * 2017-09-13 2017-10-25 Atrogi Ab New compounds and uses
GB201714745D0 (en) 2017-09-13 2017-10-25 Atrogi Ab New compounds and uses
GB201714740D0 (en) 2017-09-13 2017-10-25 Atrogi Ab New compounds and uses
GB201714734D0 (en) 2017-09-13 2017-10-25 Atrogi Ab New compounds and uses
CN109942462B (zh) * 2019-03-06 2022-01-14 宏冠生物药业有限公司 一种盐酸班布特罗的合成工艺
CN114456078B (zh) * 2022-01-19 2022-09-16 汉瑞药业(荆门)有限公司 一种(r)-n-苄基-1-(4-甲氧基苯基)丙-2-胺的制备方法

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL296701A (pt)
SE354279B (pt) 1969-06-13 1973-03-05 Draco Ab
DE1962497C3 (de) 1969-12-12 1979-09-20 C.H. Boehringer Sohn, 6507 Ingelheim Naphthylalkyl- a -hydroxyphenäthyl-amine, ihre Herstellung und diese enthaltende Arzneimittel
CH564509A5 (pt) 1969-12-12 1975-07-31 Boehringer Sohn Ingelheim
DE2010883A1 (de) 1970-03-07 1971-09-23 Troponwerke Dinklage & Co, 5000 Köln-Mülheim Pharmakologisch wirksame Aminoalkohole und Verfahren zu ihrer Darstellung
AT308139B (de) 1970-07-27 1973-06-25 Degussa Verfahren zur Herstellung von neuen basisch substituierten Alkyltheophyllinen, ihren Isomeren und Säureadditionssalzen
IT1044214B (it) 1971-04-22 1980-03-20 Zambeletti Spa L 2 idrossi 2 feniletilamine so stituite dotate di proprieta vasoattive e processo per la loro preparazione
JPS532194B2 (pt) 1973-08-10 1978-01-26
US5795564A (en) 1991-04-05 1998-08-18 Sepracor, Inc. Methods and compositions for treating pulmonary disorders using optically pure (R,R)-formoterol
US6299863B1 (en) 1992-04-03 2001-10-09 Sepracor Inc. Aerosol formulations containing micronized optically pure (R,R) formoterol for bronchodilating therapy
US6866839B2 (en) 1991-04-05 2005-03-15 Sepracor Inc. Methods and compositions for treating pulmonary disorders using optically pure (R,R)-formoterol
GB9107196D0 (en) 1991-04-05 1991-05-22 Sandoz Ag Improvements in or relating to organic compounds
DK0639186T3 (da) 1992-04-17 1999-12-13 Abbott Lab Taxolderivater
AU4408897A (en) 1996-07-05 1998-02-02 E.C. Pesterfield Associates, Inc. Method of treating retinal ischemia and glaucoma, using optically pure r- or rr- isomers of adrenergic beta-2 agonists
US6015837A (en) 1996-08-29 2000-01-18 New York Medical College Method for treating scoliosis with β2-adrenoceptor agonists
US5912264A (en) 1997-03-03 1999-06-15 Bristol-Myers Squibb Company 6-halo-or nitrate-substituted paclitaxels
WO1999016430A1 (en) 1997-09-30 1999-04-08 E.C. Pesterfield Associates, Inc. Galenic forms of r-or rr-isomers of adrenergic beta-2 agonists
ZA994264B (en) 1998-07-01 2000-01-25 Warner Lambert Co Stereoisomers with high affinity for adrenergic receptors.
AU6167599A (en) 1998-09-30 2000-04-17 United States Of America, Represented By The Secretary, Department Of Health And Human Services, The Use of a beta2 adrenergic receptor agonist in the treatment of cardiovascular disease
AR030188A1 (es) 2000-02-02 2003-08-13 Univ Florida State Res Found Compuestos de taxano sustituidos con esteres en el c7; composiciones farmaceuticas que los contienen y proceso para tratar un sujeto mamifero que sufre de una condicion que responde a los taxanos
US7045658B2 (en) 2001-03-22 2006-05-16 Glaxo Group Limited Formailide derivatives as beta2-adrenoreceptor agonists
EP1507754A1 (en) 2002-05-28 2005-02-23 Theravance, Inc. Alkoxy aryl beta-2 adrenergic receptor agonists
DK1767535T3 (da) 2002-08-23 2010-04-12 Sloan Kettering Inst Cancer Syntese af epothiloner, mellemprodukter deraf, analoge og deres anvendelse
US20050107417A1 (en) 2003-07-28 2005-05-19 Boehringer Ingelheim International Gmbh Medicaments for inhalation comprising a novel anticholinergic and a betamimetic
EP1685107B1 (en) 2003-11-03 2008-09-10 Myogen, Inc. 1,4-dihydropyridine compounds, pharmaceutical compositions, and methods for the treatment of cardiovascular disease
CA2560538A1 (en) 2004-03-22 2005-10-06 Myogen, Inc. (r)-enoximone sulfoxide and its use in the treatment of pde-iii mediated diseases
EP1781331A1 (en) 2004-08-09 2007-05-09 Université Catholique de Louvain Use of agonists and antagonists of beta-adrenoceptors for treating arterial diseases
CN101137625A (zh) 2005-01-11 2008-03-05 葛兰素集团有限公司 β2肾上腺素能激动剂的肉桂酸盐
EP2064174B1 (en) 2006-08-10 2016-10-26 The Government of the United States of America as represented by the Secretary of the Department of Health and Human Services Preparation of (r,r)- or (r,s)-fenoterol analogues and their use in treating congestive heart failure
GB0625270D0 (en) 2006-12-19 2007-01-31 Univ Leicester Angiogenesis
DK2207537T3 (en) 2007-10-02 2017-10-02 Fremont Group Ltd Systemic pro-haemostatic effect of sympathomimetics with agonistic effects on alpha-adrenergic and / or beta-adrenergic receptors in the sympathetic nervous system, related to improved clot strength
CN102740895B (zh) * 2009-12-23 2016-02-24 伊利诺伊大学董事会 纳米轭合物以及纳米轭合物配制品

Also Published As

Publication number Publication date
CA2791702C (en) 2018-05-29
BR112012022552A8 (pt) 2017-12-05
JP5837890B2 (ja) 2015-12-24
US10925840B2 (en) 2021-02-23
EP2544676A1 (en) 2013-01-16
JP2013522230A (ja) 2013-06-13
AU2014210656A1 (en) 2014-08-28
US9492405B2 (en) 2016-11-15
US20190008802A1 (en) 2019-01-10
AU2011224241B2 (en) 2014-05-08
US10130594B2 (en) 2018-11-20
WO2011112867A1 (en) 2011-09-15
US20170007556A1 (en) 2017-01-12
EP2544676B1 (en) 2018-09-19
WO2011112867A8 (en) 2012-09-27
AU2014210656B2 (en) 2016-03-17
US20200197332A1 (en) 2020-06-25
US20130005799A1 (en) 2013-01-03
AU2011224241A1 (en) 2012-09-20
CA2791702A1 (en) 2011-09-15
US10617654B2 (en) 2020-04-14

Similar Documents

Publication Publication Date Title
BR112012022552A2 (pt) uso de fenoterol e de anélogos de fenoterol no tratamento de gliobastomas e astrocitomas
IN2015DN03219A (pt)
AR092177A1 (es) Metodos para tratar o prevenir asma administrando un antagonista de il-4r
EA201590654A1 (ru) Комбинация разагилина и придопидина для лечения нейродегенеративных нарушений, в частности болезни хантингтона
EP4272757A3 (en) Modified nk-92 cells for treating cancer
MX365835B (es) Uso de akkermansia para tratar trastornos metabolicos.
PH12015500825B1 (en) Substituted benzene compounds
BR112015000150A2 (pt) composições farmacêuticas dissuasoras de abuso de liberação controlada
UA115122C2 (uk) Cd3-зв&#39;язувальна молекула, здатна до зв&#39;язування з cd3 людини і cd3, що не є людським
GT201300121A (es) Derivados de 2,3-dihidroimidazo(1,2-c)quinazolina sustituidos con aminoalcoholes que son de utilidad para tratar trastornos hiperproliferativos y enfermedades asociadas a la angiogénesis
BR112012005225B8 (pt) Uso de uma proteína de fusão actriib-fc para o tratamento de um transtorno relacionado ao osso ou associado à perda de músculo por crescimento muscular insuficiente
BR112014031088A2 (pt) métodos para o tratamento de câncer pancreático usando terapias de combinação que compreendem irinotecano lipossomal
MX2013011922A (es) Compuestos de benceno substituido.
AU2011328009A8 (en) Compounds and methods for treating pain
BR112015010039A2 (pt) tratamento de câncer com pomalidomida em um individuo com disfunção renal
BR112015022650A8 (pt) inibidores de quinase induzível por sal macrocíclico.
SG10201805267UA (en) Piperazine derivatives having multimodal activity against pain
WO2013173827A3 (en) Methods and compositions for inhibiting diseases of the central nervous system
BR112018008893A8 (pt) método para tratamento ou amenização de sintomas em um indivíduo com uma doença associada a um nervo craniano em particular, e composição farmacêutica óptica
MA32416B1 (fr) 7-sulfanylmethyl-, 7-sulfinymethyl-et 7-sulfonylmethyl-indoles substitues et leur utilisation
BR112015007095A8 (pt) derivados de di-hidro-6-azafenaleno para o tratamento de doenças do snc, oncológicas e distúrbios relacionados, composição farmacêutica compreendendoos e uso dos referidos derivados
BR112014030406A8 (pt) combinação de canabidiol fitocanabinoide com hipotermia terapêutica, e, uso de uma combinação
UA112981C2 (uk) Варіант людського gdnf
GB201206984D0 (en) New therapeutic use
ES2425448B8 (es) Uso de la obestatina para la regeneración muscular

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B06T Formal requirements before examination [chapter 6.20 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]
B12B Appeal against refusal [chapter 12.2 patent gazette]